Amendment in Export Policy of Remdesivir Injection and API Amphotericin B Injections Enoxaparin Formulation and API and Intra Venous Immunoglobulin IVIG Formulation and API regarding

## Policy Analysis Report: Amendment to Export Policy for Specific Pharmaceuticals **1. Executive Summary:** This report analyzes an amendment to the export policy concerning Remdesivir Injection and API, Amphotericin B Injections, Enoxaparin Formulation and API, and IntraVenous Immunoglobulin IVIG Formulation and API. The amendment, enacted on February 24, 2022, shifts the export policy for these pharmaceuticals from "Restricted" to "Free" with immediate effect. This change aims to facilitate the export of these critical drugs. **2. Introduction:** This report aims to provide a comprehensive overview of the amendment to the export policy of Remdesivir Injection and API, Amphotericin B Injections, Enoxaparin Formulation and API, and IntraVenous Immunoglobulin IVIG Formulation and API, as detailed in the provided official notification dated February 24, 2022. The analysis is based solely on the information contained within the notification. **3. Policy Overview:** * This report analyzes an **amendment** to existing export policies. The original policies are referenced through Notification No. 08/2015-20 dated 14.06.2021, Notification No. 07/2015-20 dated 01.06.2021, and Notification No. 50/2015-20 dated 10.01.2022. * **Core Objective:** The core objective of *this specific amendment* is to relax export restrictions on the specified pharmaceuticals, changing the policy from "Restricted" to "Free". **4. Background and Rationale:** This amendment likely aims to address issues related to the export of Remdesivir Injection and API, Amphotericin B Injections, Enoxaparin Formulation and API, and IntraVenous Immunoglobulin IVIG Formulation and API. While the notification does not explicitly state the reasons for the change, the shift from a "Restricted" to "Free" export policy suggests a potential desire to increase the availability of these drugs in the international market. This could be due to factors like increased domestic production exceeding local demand, a perceived easing of the health crisis that initially warranted export restrictions, or a strategic decision to support international healthcare needs. **5. Key Provisions / Changes:** This amendment focuses specifically on altering the export policy for the following pharmaceuticals: * Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API) * Amphotericin B Injections * Enoxaparin Formulation and API * IntraVenous Immunoglobulin (IVIG) Formulation and API **Specific Changes:** * The existing policy for the above-listed items, classified under specific ITC HS Codes (Ex 293499, Ex 300490, Ex 30049029, Ex 30049099, Ex 2942, Ex 3001, Ex 3002), was "Restricted". * The *new* rule, as introduced by the amendment, is to change the export policy to "Free" with immediate effect. * **Effect of the Change:** This change removes barriers to exporting these drugs. Previously, exporters likely had to obtain licenses or permissions to export these items. The amendment eliminates this requirement, potentially streamlining the export process and increasing export volumes. **6. Target Audience and Stakeholders:** The primary target audience and stakeholders directly affected by this amendment are: * **Pharmaceutical manufacturers** producing Remdesivir, Amphotericin B, Enoxaparin, and IVIG. * **Export companies** involved in the trade of these pharmaceuticals. * **International buyers** of these pharmaceuticals, including hospitals, healthcare organizations, and governments. **7. Implementation Aspects (Inferred):** * The **Directorate General of Foreign Trade (DGFT)**, under the Ministry of Commerce and Industry, is the responsible agency, as indicated by the notification being issued by the Director General of Foreign Trade. * The amendment is effective **immediately** from the date of the notification (February 24, 2022). * The amendment removes the need for export licenses or permissions that were previously required under the "Restricted" policy. **8. Expected Outcomes / Impact of Changes:** The likely intended outcome of this amendment is to: * **Increase exports** of the specified pharmaceuticals. * **Simplify the export process** for manufacturers and exporters. * **Potentially lower costs** associated with exporting these drugs due to the elimination of licensing requirements. * **Improve access** to these critical drugs in international markets. * The amendment may boost the competitiveness of Indian pharmaceutical manufacturers in the global market for these specific drugs. **9. Conclusion:** The amendment to the export policy, effective February 24, 2022, significantly alters the export landscape for Remdesivir Injection and API, Amphotericin B Injections, Enoxaparin Formulation and API, and IntraVenous Immunoglobulin IVIG Formulation and API. By changing the export policy from "Restricted" to "Free," the amendment is expected to facilitate increased exports, streamline the export process, and improve access to these critical pharmaceuticals in international markets. This change will have a significant impact on manufacturers, exporters, and international buyers of these drugs.

Key Entities Referenced